MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
0.8801
-0.0286
-3.15%
After Hours: 0.9070 +0.0269 +3.06% 19:44 08/21 EDT
OPEN
0.9266
PREV CLOSE
0.9087
HIGH
0.9289
LOW
0.8800
VOLUME
653.49K
TURNOVER
--
52 WEEK HIGH
3.310
52 WEEK LOW
0.7566
MARKET CAP
68.47M
P/E (TTM)
-1.4884
1D
5D
1M
3M
1Y
5Y
1D
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
TipRanks · 6d ago
Weekly Report: what happened at CRDF last week (0810-0814)?
Weekly Report · 6d ago
Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts
TipRanks · 08/15 09:01
Cardiff Oncology Cut to Market Perform From Outperform by William Blair
Dow Jones · 08/12 19:13
William Blair Downgrades Cardiff Oncology to Market Perform
Benzinga · 08/12 19:03
Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27
NASDAQ · 08/12 12:55
Piper Sandler Remains a Buy on Cardiff Oncology (CRDF)
TipRanks · 08/12 11:06
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)
TipRanks · 08/11 23:20
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.